Triosephosphate isomerase deficiency (TPID) is a glucose metabolism disorder falling into the category of disorders described as glycolytic enzymopathies; TPID exhibits autosomal recessive inheritance. It is unique among the glycolytic enzyme defects, most of which manifest clinically as chronic hemolytic anemias, since it is also associated with progressive and severe neurological dysfunction. The human gene implicated in this disease is triosephosphate isomerase (TPI1), which catalyzes the isomerization between dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. There is a single Drosophila ortholog, Dmel\Tpi, for which amorphic and loss-of-function alleles, RNAi-targeting constructs, and alleles caused by insertional mutagenesis have been generated.
The fly gene has been replaced in situ with a wild-type human Hsap\TPI1 gene (with modified codon usage) and with a human variant implicated in TPID. Heterologous rescue (functional complementation) has been demonstrated. Variant(s) implicated in human disease tested (as transgenic human gene, TPI1): the I170V (I208V) variant form of the human gene has been introduced into flies.
Amorphic mutations in the Dmel\Tpi gene are recessive lethals. Animals homozygous or hemizygous for different missense mutations show phenotypes including reduced longevity, progressive locomotor deficiency, induced paralytic phenotypes, and neural degeneration; phenotypes become worse under conditions of oxidative stress; at a cellular level, synaptic vesicle dysfunction is observed. A particular human variant, TPI1:Arg227Gln (referred to in FBrf0242891 as Arg190Gln), was introduced to Drosophila via multiple analogous mutations (Arg changed to Ala, Lys, Ser, and Leu) in the fly gene, and all variants other than Arg187Lys in Dmel\Tpi show defects.
[updated November 2019 by FlyBase; FBrf0222196]
[TRIOSEPHOSPHATE ISOMERASE DEFICIENCY; TPID](https://omim.org/entry/615512)
[TRIOSEPHOSPHATE ISOMERASE 1; TPI1](https://omim.org/entry/190450)
Many glycolytic enzymopathies have been described that manifest clinically as chronic hemolytic anemia. Triosephosphate isomerase (TPI) deficiency, is unique among the glycolytic enzyme defects since it is associated with progressive neurological dysfunction and frequently with childhood death. (Orosz et al., 2006; PMID: 17424909)
Triosephosphate isomerase deficiency is characterized by congenital hemolytic anemia, and progressive neuromuscular dysfunction beginning in early childhood. The neurologic syndrome is variable, but usually includes lower motor neuron dysfunction with hypotonia, muscle weakness and atrophy, and hyporeflexia. Many patients die from respiratory failure in childhood. (summary by Fermo et al., 2010; pubmed:20374271) [from MIM:615512; 2017.01.30]
Triosephosphate isomerase deficiency (TPID) is caused by homozygous or compound heterozygous mutation in the TPI1 gene (autosomal recessive). [from MIM:615512; 2017.01.30]
Intracellular accumulation of dihydroxyacetone phosphate (DHAP) is observed, particularly in red blood cells. (summary by Fermo et al., 2010; pubmed:20374271) [from MIM:615512; 2017.01.30]
The TPI1 gene encodes triosephosphate isomerase 1, a homodimeric enzyme that catalyzes the interconversion of dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate during glycolysis and gluconeogenesis (summary by Chang et al., 1993; pubmed:8503454). [from MIM:190450; 2017.01.30]
One to one (1 human to 1 Drosophila).
High-scoring ortholog of human TPI1 (1 Drosophila to 1 human). Dmel\Tpi shares 63% identity and 74% similarity with human TPI1.